ClinicalTrials.gg
CompletedNCT02104427Updated Apr 19, 2021Results posted

PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

A Phase 2 interventional study of TG-0054 combined with G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease, sponsored by GPCR Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-19.

Sponsored by GPCR Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma — 1 open to participants now, 1 under way, 1 of them phase 3. Granulocyte Colony-Stimulating Factor · Multiple Myeloma.

Enrollment
24th of 28
12 · median 38
Started
2015
with 1 other
Phase 2
17 of 28
none open now
Registered
23rd of 28
by date

Among the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, this one is the 24th largest by enrollment, is one of 2 that started in 2015, is one of 17 in phase 2, and was the 23rd registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Granulocyte Colony-Stimulating Factor

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.

03

Conditions studied

  • Multiple Myeloma
  • Non-Hodgkin Lymphoma
  • Hodgkin Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 18 to 75 years of age inclusive;
  • Patients with confirmed pathology diagnosis of MM, NHL or HD;
  • Potential candidate for stem cell transplantation at Investigator's discretion;
  • > 4 weeks since last cycle of chemotherapy prior to the study drug administration;
  • Total dose of melphalan received ≦ 200 mg in the most recent chemotherapy treatment;
  • (ECOG) performance status of 0 or 1;
  • Recovered from all acute toxic effects of prior chemotherapy at Investigator's discretion;
  • White blood cell (WBC) count ≧ 3.0*10\^9/L on screening laboratory assessments;
  • ≧ 1.5*10\^9/L on screening laboratory assessments;
  • count ≧ 100*10\^9/L on screening laboratory assessments;
  • Serum creatinine ≦ 2.2 mg/dL on screening laboratory assessments;
  • (AST), alanine aminotransferase (ALT), and total \< 2 x (ULN) on screening laboratory assessments;
  • Negative for (HIV);
  • Adequate cardiac and pulmonary function to undergo leukapheresis at Investigator's discretion;
  • For females, one of the following criteria must be fulfilled:

    1. At least one year , or
    2. Surgically sterile, or
    3. Willing to use a double-barrier method [intrauterine device (IUD) plus condom, spermicidal gel plus condom] of from study Day 1 until 28 days after the last dose of TG-0054;
  • Males must be willing to use a reliable form of contraception (use of a condom or a partner fulfilling the above criteria) from study Day 1 until 28 days after the last dose of TG-0054;
  • Able to provide the signed .

Exclusion criteria

Exclusion Criteria:

  • Received radiation therapy to the pelvis;
  • Received > 6 cycles of lenalidomide;
  • Evidence of bone marrow involvement of lymphoma in NHL patients;
  • Failed previous stem cell collection [failed to collect 2.0*10\^6 CD34+ cells/kg within 4 leukapheresis sessions after receiving granulocyte colony-stimulating factor (G-CSF)];
  • Patients who have undergone previous stem cell transplantation procedure;
  • Received G-CSF within 2 weeks prior to the study drug administration;
  • History of other cancer within the past 5 years excluding MM, NHL, HD, basal cell or squamous cell carcinoma of the skin;
  • History of other hematologic disorders including bleeding or thromboembolic disease being treated with anti-coagulant;
  • History of poor and uncontrollable cardiovascular or pulmonary disease such as myocardial infarction, cardiac arrhythmias, , stroke or (COPD) patients hospitalized more than two times a year due to underlying disease;
  • Diagnosis of sickle cell anemia or documented sickle cell trait;
  • Patients with proliferative retinopathy;
  • Uncontrollable with MM, NHL or HD, or carcinomatous meningitis, at Investigator's discretion;
  • Any infection required antibiotic treatment or unexplained fever above 38 °C within 3 days prior to dosing;
  • Pregnant or breast-feeding;
  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study;
  • Received any other drug within 1 month before entering the study;
  • Received prior treatment with TG-0054 but withdrew early from this study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    TG-0054 combined with G-CSF

    1. G-CSF: 10 μg/kg/day, administrated via SC injections from Day 1 to Day 8; 2. TG-0054: 3.14 mg/kg, administrated via 15-min IV infusion from Day 5 to Day 9 as needed to reach the target collection goal

    Drug: TG-0054 combined with G-CSF

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Patients From Whom a Total Number of CD34+ Cells ≥5.0 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions

    The primary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥5.0 x 10\^6 cells/kg was collected within the first 4 leukapheresis sessions. For the primary efficacy endpoint, each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) the first 4 leukapheresis sessions.

    Time frame: Day 5 to Day 8

Secondary outcomes

  1. Proportion of Patients From Whom a Total Number of CD34+ Cells ≥2.5 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions

    The secondary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥2.5 x 10\^6 cells/kg was collected within the first 4 leukapheresis sessions. Each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) the first 4 leukapheresis sessions.

    Time frame: Day 5 to Day 8

  2. Proportion of Patients Who Mobilized the Targeted Total Number of CD34+ Cells (≥6.0 x 10^6 Cells/kg) Within 5 Leukapheresis Sessions

    The secondary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥6.0 x 10\^6 cells/kg was collected within 5 leukapheresis sessions. Each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) 5 leukapheresis sessions.

    Time frame: Day 5 to Day 9

  3. the Pharmacodynamics (PD) Following Treatment With TG-0054 When Combined With G-CSF

    determine circulating CD34+ cell counts in peripheral blood

    Time frame: Day 5 (1st leukapheresis session) to Day 6 (2nd leukapheresis session)

07

Results

Posted Dec 13, 2017

Participant flow

Participant flow — Overall Study
MilestoneTG-0054 Combined With G-CSF
Started12
Completed12
Not completed0

Outcome measures

PrimaryProportion of Patients From Whom a Total Number of CD34+ Cells ≥5.0 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions

The primary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥5.0 x 10\^6 cells/kg was collected within the first 4 leukapheresis sessions. For the primary efficacy endpoint, each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) the first 4 leukapheresis sessions.

Time frame:
Day 5 to Day 8
Reported as:
Number · Proportion of participants
Proportion of Patients From Whom a Total Number of CD34+ Cells ≥5.0 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions
Proportion of participantsWithin 1 Leukapheresis SessionWithin 2 Leukapheresis SessionsWithin 3 Leukapheresis SessionsWithin 4 Leukapheresis Sessions
Overall0.50000 (0.2109 to 0.7891)0.9167 (0.6152 to 0.9979)0.9167 (0.6152 to 0.9979)0.9167 (0.6152 to 0.9979)
Multiple Myeloma0.6667 (0.2993 to 0.9251)0.8889 (0.5175 to 0.9972)0.8889 (0.5175 to 0.9972)0.8889 (0.5175 to 0.9972)
Non-Hodgkin Lymphoma or Hodgkin Disease0.0000 (0.0000 to 0.0000)1.0000 (0.2924 to 1.0000)1.0000 (0.2924 to 1.0000)1.0000 (0.2924 to 1.0000)
SecondaryProportion of Patients From Whom a Total Number of CD34+ Cells ≥2.5 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions

The secondary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥2.5 x 10\^6 cells/kg was collected within the first 4 leukapheresis sessions. Each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) the first 4 leukapheresis sessions.

Time frame:
Day 5 to Day 8
Reported as:
Number · Proportion of patients
Proportion of Patients From Whom a Total Number of CD34+ Cells ≥2.5 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions
Proportion of patientsWithin 1 Leukapheresis SessionWithin 2 Leukapheresis SessionsWithin 3 Leukapheresis SessionsWithin 4 Leukapheresis Sessions
Overall0.9167 (0.6152 to 0.9979)0.9167 (0.6152 to 0.9979)0.9167 (0.6152 to 0.9979)0.9167 (0.6152 to 0.9979)
Multiple Myeloma0.8889 (0.5175 to 0.9972)0.8889 (0.5175 to 0.9972)0.8889 (0.5175 to 0.9972)0.8889 (0.5175 to 0.9972)
Non-Hodgkin Lymphoma or Hodgkin Disease1.0000 (0.2924 to 1.0000)1.0000 (0.2924 to 1.0000)1.0000 (0.2924 to 1.0000)1.0000 (0.2924 to 1.0000)
SecondaryProportion of Patients Who Mobilized the Targeted Total Number of CD34+ Cells (≥6.0 x 10^6 Cells/kg) Within 5 Leukapheresis Sessions

The secondary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥6.0 x 10\^6 cells/kg was collected within 5 leukapheresis sessions. Each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) 5 leukapheresis sessions.

Time frame:
Day 5 to Day 9
Reported as:
Number · Proportion of patients
Proportion of Patients Who Mobilized the Targeted Total Number of CD34+ Cells (≥6.0 x 10^6 Cells/kg) Within 5 Leukapheresis Sessions
Proportion of patientsWithin 1 Leukapheresis SessionWithin 2 Leukapheresis SessionsWithin 3 Leukapheresis SessionsWithin 4 Leukapheresis SessionsWithin 5 Leukapheresis Sessions
Overall0.5000 (0.2109 to 0.7891)0.6667 (0.3489 to 0.9008)0.6667 (0.3489 to 0.9008)0.6667 (0.3489 to 0.9008)0.6667 (0.3489 to 0.9008)
Multiple myeloma0.6667 (0.2993 to 0.9251)0.8889 (0.5175 to 0.9972)0.8889 (0.5175 to 0.9972)0.8889 (0.5175 to 0.9972)0.8889 (0.5175 to 0.9972)
Non-Hodgkin Lymphoma or Hodgkin Disease0.0000 (0.0000 to 0.0000)0.0000 (0.0000 to 0.0000)0.0000 (0.0000 to 0.0000)0.0000 (0.0000 to 0.0000)0.0000 (0.0000 to 0.0000)
Secondarythe Pharmacodynamics (PD) Following Treatment With TG-0054 When Combined With G-CSF

determine circulating CD34+ cell counts in peripheral blood

Time frame:
Day 5 (1st leukapheresis session) to Day 6 (2nd leukapheresis session)
Reported as:
Median · cells/µL
the Pharmacodynamics (PD) Following Treatment With TG-0054 When Combined With G-CSF
cells/µLPre-dose4h Post-infusion6h Post-infusionPre-leukapheresisPost-leukapheresis
Day 5 (1st leukapheresis session)32.50 (1.00 to 123.00)43.50 (0.00 to 141.00)42.00 (1.00 to 122.00)60.50 (1.00 to 206.00)35.50 (3.00 to 119.00)
Day 6 (2nd leukapheresis session)16.00 (1.00 to 59.50)28.00 (14.00 to 45.00)20.00 (0.00 to 45.00)34.00 (2.00 to 70.00)21.00 (16.00 to 45.00)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
10 µg/kg/Day G-CSF Alone0/12 (0%)0/12 (0%)2/12 (16.7%)
10 µg/kg/Day G-CSF + 3.14 mg/kg TG-00540/12 (0%)0/12 (0%)6/12 (50%)
Overall0/12 (0%)0/12 (0%)7/12 (58.3%)
Most frequent other events
Most frequent other events
Event10 µg/kg/Day G-CSF Alone10 µg/kg/Day G-CSF + 3.14 mg/kg TG-0054Overall
Bone painMusculoskeletal and connective tissue disorders2/120/122/12
HypocalcaemiaMetabolism and nutrition disorders1/120/121/12
DiarrhoeaGastrointestinal disorders0/121/121/12
Dry mouthGastrointestinal disorders0/121/121/12
NauseaGastrointestinal disorders0/121/121/12
HypokalaemiaMetabolism and nutrition disorders0/121/121/12
Oedema peripheralGeneral disorders0/121/121/12
Platelet count decreasedInvestigations0/121/121/12
ParaesthesiaNervous system disorders0/121/121/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)TG-0054 Combined With G-CSF
Mean58 (41 to 69)
Sex: Female, Male
Sex: Female, Male(Participants)TG-0054 Combined With G-CSF
Female4
Male8
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TG-0054 Combined With G-CSF
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander1
Black or African American2
White8
More than one race0
Unknown or Not Reported0
Weight
Weight(kg)TG-0054 Combined With G-CSF
Mean82.4 (54.6 to 114.0)
BMI
BMI(kg/m^2)TG-0054 Combined With G-CSF
Mean29.3 (21.9 to 37.1)
08

Study locations

2 sites
  • Stony Brook University Hospital
    Stony Brook, New York 11794, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2017, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2014
First posted
Apr 4, 2014
Start
Feb 2015
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Results first posted
Dec 13, 2017
Last update
Apr 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02104427
Lead sponsor
GPCR Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 4, 2014
Start date
Feb 2015
Primary completion
Nov 2015
Completion
Nov 2015
Results posted
Dec 13, 2017
Last update
Apr 19, 2021

Study contacts

Michael M Schuster, MD
principal investigator · Stony Brook University Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Burixafor · Granulocyte Colony-Stimulating Factor

Start the discussion